Modified Disease Activity Score at 3 Months Is a Significant Predictor for Rapid Radiographic Progression at 12 Months Compared With Other Measures in Patients With Rheumatoid Arthritis.
Journal
ACR open rheumatology
ISSN: 2578-5745
Titre abrégé: ACR Open Rheumatol
Pays: United States
ID NLM: 101740025
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
received:
05
12
2019
accepted:
29
01
2020
pubmed:
15
3
2020
medline:
15
3
2020
entrez:
15
3
2020
Statut:
ppublish
Résumé
Progressive rheumatoid arthritis (RA) is responsible for joint damage causing disabilities, but there is no agreement on which disease measures best predict radiographic progression. We aimed to determine which disease activity measures, including the disease activity score, the modified disease activity score in 28 joints with C-reactive protein testing (M-DAS28-CRP), the Clinical Disease Activity Index, and the Health Assessment Questionnaire Disability Index, at baseline and 3 months best predicted rapid radiographic progression (RRP) in patients with early RA. Data were used from PREMIER, a 2-year, multicenter, double-blind, active comparator controlled study with methotrexate (MTX)-naïve patients with RA and active disease for less than 3 years. Treatments included adalimumab plus oral MTX, adalimumab, or oral MTX. Only patients in the MTX arm were analyzed in this study. RRP was defined as a change in the modified total Sharp score of less than 3.5 at month 12. The logistic regression analysis assessed the impact of measures at baseline and 3 months on RRP at 12 months. Best cutoff points of the M-DAS28-CRP were also estimated by using area under the receiver operating characteristic curve. A total of 149 patients were included (female patients: n = 113 [75.8%]; positive rheumatoid factor: n = 127 [85.2%]; mean [SD] age: 52.9 [13.3] years; mean [SD] disease duration: 0.8 [0.9] year; mean [SD] M-DAS28-CRP: 6.3 [0.9]). After adjusting for potential confounders, only the M-DAS28-CRP at baseline (adjusted odds ratio [AOR] = 3.29; 95% confidence interval [CI]: 1.70-6.36) and 3 months (AOR = 2.56; 95% CI: 1.43-4.56) strongly predicted RRP at 12 months. M-DAS28-CRP of 4.5 and 2.6 at baseline and 3 months, respectively, maximized positive and negative predictive values for prediction of RRP. The M-DAS28-CRP was a stronger predictor at baseline and 3 months for RRP compared with other disease activity measures. Removing tender joint count and patient global assessment from the DAS28-CRP improves prediction of RRP.
Identifiants
pubmed: 32170838
doi: 10.1002/acr2.11123
pmc: PMC7077779
doi:
Types de publication
Journal Article
Langues
eng
Pagination
188-194Informations de copyright
© 2020 The Authors. ACR Open Rheumatology published by Wiley Periodicals, Inc. on behalf of American College of Rheumatology.
Références
BMC Musculoskelet Disord. 2011 May 30;12:120
pubmed: 21624120
Cancer. 1950 Jan;3(1):32-5
pubmed: 15405679
Arthritis Rheumatol. 2014 Apr;66(4):794-802
pubmed: 24757132
Rheumatology (Oxford). 2019 Dec 09;:
pubmed: 31819995
J Rheumatol. 2014 Jan;41(1):5-14
pubmed: 24241487
Ann Rheum Dis. 2009 Jun;68(6):823-7
pubmed: 18593759
Clin Exp Rheumatol. 2014 Sep-Oct;32(5 Suppl 85):S-23-8
pubmed: 25365085
Arthritis Rheum. 2006 Jan;54(1):26-37
pubmed: 16385520
J Rheumatol. 2016 Jul;43(7):1300-5
pubmed: 27084908
Clin Exp Rheumatol. 2014 Nov-Dec;32(6):869-77
pubmed: 25327997
Clin Pharmacol Ther. 2012 Apr;91(4):607-20
pubmed: 22357455
Ann Rheum Dis. 2014 Jul;73(7):1316-22
pubmed: 24550173
Rheumatology (Oxford). 2016 Feb;55(2):327-34
pubmed: 26361879
Best Pract Res Clin Rheumatol. 2011 Aug;25(4):497-507
pubmed: 22137920
Arthritis Rheum. 1988 Mar;31(3):315-24
pubmed: 3358796
Rheumatology (Oxford). 2000 Feb;39(2):122-32
pubmed: 10725061
Arthritis Rheum. 1998 Oct;41(10):1845-50
pubmed: 9778226
Hand Clin. 2011 Feb;27(1):11-20
pubmed: 21176795
Arthritis Rheum. 1995 Jan;38(1):44-8
pubmed: 7818570
Qual Life Res. 2016 Oct;25(10):2619-2632
pubmed: 27052421